Life-saving procedures of an emergency protocol to combat fatal ambushes of viral or bacterial pathogens are listed below for immediate dissemination and implementation. This unique protocol of serum therapy commands the highest benefits-versus-risks ratio, and is safe, efficacious, user-friendly and inexpensive to implement. A formal evaluation is presented to support upgrading convalescent plasma therapy to serum therapy in the context of presenting fewer donor antigens, thus evoking less lethal sensitization to obtain greater safety and efficacy in treatment.
References
[1]
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J.K., et al. (2015) The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-Analysis. The Journal of Infectious Diseases, 211, 80-90. https://doi.org/10.1093/infdis/jiu396
[2]
Law, P.K. (2020) Emergent Serum Therapy and Antibody Medicine to Counteract Sudden Attacks of COVID-19 and Other Pathogenic Epidemics. Open Journal of Regenerative Medicine, 9, 1-7. https://www.scirp.org/journal/ojrm https://doi.org/10.4236/ojrm.2020.91001
[3]
Law, P.K., Bertorini, T., Goodwin, T.G., Chen, M., Fang, Q.W., Li, H.J., et al. (1990) Dystrophin Production Induced by Myoblast Transfer Therapy in Duchenne Muscular Dystrophy. The Lancet, 336, 114-115. https://doi.org/10.1016/0140-6736(90)91628-N
Law, P.K. (1993) Myoblast Transfer Therapy. The Lancet, 341, 247. https://doi.org/10.1016/0140-6736(93)90115-W
[6]
Law, P.K., Goodwin, T.G., Fang, Q., Duggirala, V., Larkin, C., Florendo, J.A., et al. (1992) Feasibility, Safety, and Efficacy of Myoblast Transfer Therapy on Duchenne Muscular Dystrophy Boys. Cell Transplantation, 1, 235-244. https://doi.org/10.1177/0963689792001002-305
[7]
Law, P.K., Goodwin, T.G., Fang, Q., Vastagh, G., Jordan, T., Jackson, T., Kenny, S., Duggirala, V., Larkin, C., Chase, N., Phillips, W., Williams, G., Neel, M., Krahn, T. and Holcomb, R. (1998) Myoblast Transfer as a Platform Technology of Gene Therapy. Gene Therapy and Molecular Biology, 1, 345-363.
[8]
Law, P., et al. (2000) World’s First Human Myoblast Transfer into the Heart. Frontiers in Physiology, A85.
[9]
Law, P.K., et al. (2003) Myoblast Genome Therapy and the Regenerative Heart. In: Kipshidze, N. and Serruys, P., Eds., Handbook of Cardiovascular Cell Transplantation, Martin Dunitz, Ltd., London, 241-257. https://doi.org/10.3109/9780203640685-18
[10]
Law, P. (2006) Heart Cell Therapy Symposium. Journal of Geriatric Cardiology, 3, 131-180.
[11]
Ye, L., Haider, H.Kh. Tan, R.S., Toh, W.C., Law, P.K., Tan, W.B., Su, L.P., Zhang, W., Ge, R.W., Zhang, Y., Lim, Y.T. and Sim, E.K.W. (2007) Transplantation of Nanoparticle Transfected Skeletal Myoblasts Overexpressing Vascular Endothelial Growth Factor-165 for Cardiac Repair. Circulation, 116, I113-I120. https://doi.org/10.1161/CIRCULATIONAHA.106.680124
[12]
Ye, L., Haider, H.Kh., Tan, R.S., Su, L.P., Law, P.K., Wei, Z. and Sim, E.K.W. (2008) Angiomyogenesis Using Liposome Based Vascular Endothelial Growth Factor-165 Transfection with Skeletal Myoblast for Cardiac Repair. Biomaterials, 29, 2125-2137. https://doi.org/10.1016/j.biomaterials.2008.01.014
[13]
Law, P.K. and Law, D.M. (2011) Human Myoblast Genome Therapies and Devices in Regenerative Medicine. Recent Patents on Regenerative Medicine, 1, 88-117. https://doi.org/10.2174/2210297311101010088
[14]
Law, P.K., Law, D.L.M., Lu, P., et al. (2004) The World’s First Myoblast Study of Type II Diabetic Patients. Business Briefing: North American Pharmacotherapy, No. 2, 361.
[15]
Ma, J.H., Su, L.P., Zhu, J., et al. (2013) Skeletal Myoblast Transplantation on Gene Expression Profiles of Insulin Signaling Pathway and Mitochondrial Biogenesis and Function in Skeletal Muscle. Diabetes Research and Clinical Practice, 102, 43-52. https://doi.org/10.1016/j.diabres.2013.08.006
[16]
Ye, L., Lee, K.O., Su, L.P., et al. (2009) Skeletal Myoblast Transplantation for Attenuation of Hyperglycaemia, Hyperinsulinaemia and Glucose in Tolerance in a Mouse Model of Type 2 Diabetes Mellitus. Diabetologia, 52, 1925-1934. https://doi.org/10.1007/s00125-009-1421-9
[17]
Law, P.K. (2016) Disease Prevention and Alleviation by Myoblast Transplantation. Open Journal of Regenerative Medicine, 5, 25-43. https://doi.org/10.4236/ojrm.2016.52003
[18]
Law, P.K., Song, S.J., Lu, P., Gao, Y., Ao, M., Zhao, H., Bai, L., Guo, K. and Law, D.M. (2017) World’s First Myoblast Treatment of Human Cancer Found Safe and Efficacious. Open Journal of Regenerative Medicine, 6, 1-16. https://doi.org/10.4236/ojrm.2017.61001
[19]
Law, P.K., et al (2019) Myoblasts Provide Safe and Effective Treatments for Hereditary Muscular Dystrophies, Cardiomyopathies, Type 2 Diabetes, Solid Tumors and Aging. In: Haider, K.H. and Aziz, S., Eds., Stem Cells—From Hype to Real Hope, Walter de Gruyter GmbH, Berlin/Boston, 71-97. https://doi.org/10.1515/9783110587043-004
[20]
Yang, X.M. and Hou, J.F. (2020) The Current Status of Convalescent Plasma’s Application in Acute Viral Infectious Diseases and Its Prospects in the Treatment of New Coronavirus Pneumonia. Chinese Journal of Biologicals, 1-5.
[21]
Shanwell, A., Andersson, T.M.-L., Rostgaard, K., et al. (2009) Post-Transfusion Mortality among Recipients of ABO-Compatible but Non-Identical Plasma. Vox Sanguinis, 96, 316-323. https://doi.org/10.1111/j.1423-0410.2009.01167.x
[22]
Inaba, K., Branco, B., Rhee, P., et al. (2010) Impact of ABO-Identical vs ABO- Compatible Nonidentical Plasma Transfusion in Trauma Patients. The Archives of Surgery, 145, 899-906. https://doi.org/10.1001/archsurg.2010.175
[23]
Berséus, O., Boman, K., Nessen, S.C., et al. (2013) Risks of Hemolysis Due to Anti-A and Anti-B Caused by the Transfusion of Blood or Blood Components Containing ABO-Incompatible Plasma. Transfusion, 53, 114S-123S. https://doi.org/10.1111/trf.12045
[24]
Cao, W.C., Liu, W., Zhang, P.H., et al. (2007) Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery. The New England Journal of Medicine, 357, 1162-1163. https://doi.org/10.1056/NEJMc070348
